C McLeod

1.0k total citations
27 papers, 835 citations indexed

About

C McLeod is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Economics and Econometrics. According to data from OpenAlex, C McLeod has authored 27 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 5 papers in Economics and Econometrics. Recurrent topics in C McLeod's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (3 papers). C McLeod is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (3 papers). C McLeod collaborates with scholars based in United Kingdom, Qatar and Canada. C McLeod's co-authors include Y Dündar, Angela Boland, A Bagust, Rumona Dickson, T Walley, Nigel Fleeman, J Greenhalgh, Ruaraidh Hill, Rubén Mújica-Mota and Munir Pirmohamed and has published in prestigious journals such as SHILAP Revista de lepidopterología, Health Technology Assessment and PharmacoEconomics.

In The Last Decade

C McLeod

26 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C McLeod United Kingdom 16 178 134 123 104 99 27 835
Lucie Opatrny Canada 14 84 0.5× 62 0.5× 158 1.3× 120 1.2× 27 0.3× 28 938
G. Aulagner France 18 141 0.8× 119 0.9× 110 0.9× 33 0.3× 55 0.6× 79 1.2k
Francis Vekeman United States 22 233 1.3× 177 1.3× 80 0.7× 47 0.5× 32 0.3× 89 1.3k
Thomas Wilke Germany 23 146 0.8× 88 0.7× 212 1.7× 57 0.5× 45 0.5× 166 1.8k
Suzanne M. Norby United States 16 165 0.9× 34 0.3× 141 1.1× 411 4.0× 34 0.3× 42 1.7k
Andrew S. Allegretti United States 23 192 1.1× 40 0.3× 410 3.3× 26 0.3× 52 0.5× 76 1.4k
Kathleen Gondek United States 16 249 1.4× 203 1.5× 106 0.9× 112 1.1× 18 0.2× 43 1.0k
TR Einarson Canada 13 45 0.3× 71 0.5× 68 0.6× 282 2.7× 27 0.3× 38 1.1k
Diogo Mendes Portugal 16 68 0.4× 129 1.0× 100 0.8× 71 0.7× 20 0.2× 40 796
Anand Rajeswaran Switzerland 6 113 0.6× 102 0.8× 321 2.6× 176 1.7× 17 0.2× 6 884

Countries citing papers authored by C McLeod

Since Specialization
Citations

This map shows the geographic impact of C McLeod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C McLeod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C McLeod more than expected).

Fields of papers citing papers by C McLeod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C McLeod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C McLeod. The network helps show where C McLeod may publish in the future.

Co-authorship network of co-authors of C McLeod

This figure shows the co-authorship network connecting the top 25 collaborators of C McLeod. A scholar is included among the top collaborators of C McLeod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C McLeod. C McLeod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martin, Antony P., Sarah Richards, Alan Haycox, et al.. (2015). Plerixafor is cost‐effective compared to conventional chemotherapy for first‐line haematopoietic stem cell mobilization: Data from the PHANTASTIC trial. Journal of Clinical Apheresis. 8 indexed citations
2.
Haycox, Alan, Munir Pirmohamed, C McLeod, Rachel Houten, & Sarah Richards. (2014). Through a Glass Darkly: Economics and Personalised Medicine. PharmacoEconomics. 32(11). 1055–1061. 15 indexed citations
3.
Houten, Rachel, Allan Wailoo, Páll Jónsson, & C McLeod. (2013). Variations in primary care prescribing: lessons to be learnt for GP commissioners. Primary Health Care Research & Development. 15(1). 111–116.
4.
5.
Bagust, A, J Greenhalgh, Angela Boland, et al.. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. PharmacoEconomics. 28(6). 439–448. 36 indexed citations
6.
Fleeman, Nigel, Y Dündar, Rumona Dickson, et al.. (2010). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. The Pharmacogenomics Journal. 11(1). 1–14. 87 indexed citations
7.
Fleeman, Nigel, A Bagust, C McLeod, et al.. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment. 14(Suppl 1). 47–53. 25 indexed citations
8.
Greenhalgh, J, C McLeod, A Bagust, et al.. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment. 14(Suppl 2). 33–39. 10 indexed citations
9.
Greenhalgh, J, C McLeod, A Bagust, et al.. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment. 14(Suppl 2). 33–39. 16 indexed citations
10.
Jack, Barbara, Angela Boland, Rumona Dickson, James Stevenson, & C McLeod. (2009). Best supportive care in lung cancer trials is inadequately described: a systematic review. European Journal of Cancer Care. 19(3). 293–301. 12 indexed citations
11.
12.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment. 13(Suppl 3). 49–54. 8 indexed citations
13.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment. 13(Suppl 3). 49–54. 47 indexed citations
14.
Dündar, Y, A Bagust, Juliet Hounsome, et al.. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma. Health Technology Assessment. 13(Suppl 1). 23–28. 4 indexed citations
15.
16.
Hockenhull, Jo, Kerry Dwan, Angela Boland, et al.. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technology Assessment. 12(12). iii–iv, xi. 79 indexed citations
17.
Dündar, Y, A Bagust, Rumona Dickson, et al.. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technology Assessment. 11(1). 1–90. 16 indexed citations
18.
McLeod, C, A Bagust, Angela Boland, et al.. (2007). Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment. 11(28). 1–158, iii. 141 indexed citations
19.
Hill, Ruaraidh, Angela Boland, Y Dündar, et al.. (2007). Drug-eluting stents: a systematic review and economic evaluation. Health Technology Assessment. 11(46). iii, xi–221. 48 indexed citations
20.
Black, Corri, A Bagust, Angela Boland, et al.. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technology Assessment. 10(3). iii–iv, ix. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucie Opatrny Breakdown of academic impact, for papers by G. Aulagner Breakdown of academic impact, for papers by Francis Vekeman Breakdown of academic impact, for papers by Thomas Wilke Breakdown of academic impact, for papers by Suzanne M. Norby Breakdown of academic impact, for papers by Andrew S. Allegretti Breakdown of academic impact, for papers by Kathleen Gondek Breakdown of academic impact, for papers by TR Einarson Breakdown of academic impact, for papers by Diogo Mendes Breakdown of academic impact, for papers by Anand Rajeswaran
Rankless by CCL
2026